S1PR modulators, which inhibit S1P-S1PR1 signaling, treat IBD by inhibiting the infiltration of lymphocytes into the inflamed intestinal lamina propria (Deguchi et al., 2006; Pérez-Jeldres et al., 2019). This evidence concerns the gene S1PR1 and inflammatory bowel disease.